![MAPS_psychedelic](https://pharmaphorum.com/wp-content/uploads/2021/05/MAPS_psychedelic.jpg)
MDMA on track for 2023 approval as PTSD therapy, says develo...
A medicine based on MDMA – the active ingredient in recreational drug ecstasy – is on the cusp of FDA approval as a treatment for post-traumatic stress disorder (PTSD), according to the org